



03-03-08

DFW

PTO/SB/21 (01-08)

Approved for use through 02/29/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/617,489	
	Filing Date	July 10, 2003	
	First Named Inventor	Thomas L. CANTOR	
	Art Unit	1641	
	Examiner Name	C. Cheu	
Total Number of Pages in This Submission	11	Attorney Docket Number	532212000623

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement – Supplemental (8 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO/SB/08A/B (1 page + duplicate) References (14) Return Receipt Postcard
Remarks Customer No. 25225		


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	MORRISON & FOERSTER LLP		
Signature			
Printed name	Peng Chen		
Date	February 28, 2008	Reg. No.	43,543

I hereby certify that this paper is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 956952276 US, on the date shown below in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: February 28, 2008

Signature: (Anthony Matson)



hereby certify that this paper is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 956952276 US, on the date shown below in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: February 28, 2008

Signature: _____

(Anthony Matson)

Patent

Docket No. 532212000623

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Thomas L. CANTOR et al.

Serial No.: 10/617,489

Filing Date: July 10, 2003

For: METHODS, KITS AND ANTIBODIES
FOR DETECTING PARATHYROID
HORMONE

Examiner: C. Cheu

Group Art Unit: 1641

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to consider and make these documents of record.

Document number 1 is from an opposition against EP Patent No. 1,151,307, which is related to the present application. Document numbers 2-4 are depositions from Patent Interference No. 105,575 (MPT), between Application No. 10/641,780 and U.S. Patent No. 6,838,264. Application No. 10/641,780 is related to the present application.

Document numbers 5-11 are from *Scantibodies Laboratory, Inc. v. Immutopics, Inc.*, currently pending in the United States District Court for the Central District of California, Case No.

sd-412947

CV 04-08871 MRP (MANx). This litigation involves U.S. Patent No. 6,689,566. The present application is a Continuation-in-Part of U.S. Patent No. 6,743,590, which is a Continuation-in-Part of U.S. Patent No. 6,689,566. Scantibodies Laboratory, Inc. is the assignee of U.S. Patent No. 6,689,566 and the present application. Document numbers 12-14 are from the reexamination of U.S. Patent No. 6,689,566.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of __ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Applicants point out that in the Petition to Withdraw Application from Issue pursuant to 37 C.F.R. 1.313(c)(2), submitted on January 25, 2008, applicants listed the Supplemental Information Disclosure Statements submitted after the mailing of the Notice of Allowance on January 4, 2007. Current with or after the submission of the Petition to Withdraw Application from Issue on January 25, 2008, the following Supplemental Information Disclosure Statements have further been submitted:

- Supplemental Information Disclosure Statement submitted on January 25, 2008 with 2 references;
- Supplemental Information Disclosure Statement submitted on February 5, 2008 with 3 references;
- Supplemental Information Disclosure Statement submitted concurrently with 14 references; and
- Supplemental Information Disclosure Statement submitted on February 1, 2008 with a Petition To Expunge and 2 references.

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

As pointed out previously, one of the parent patents of the present application, U.S. Patent No. 6,689,566 ('566 patent), is currently involved in litigation. As part of that litigation, the

defendant in that litigation, Immutopics, Inc., has asserted non-infringement, invalidity and unenforceability of the '566 patent and has submitted various documents related to its non-infringement, invalidity and unenforceability assertions in that litigation. In the Supplemental Information Disclosure Statement submitted on January 25, 2008, applicants submitted the following Immutopics' documents from that litigation:

- Memorandum of Points and Authorities in Support of Defendants' and Counterclaimants' Motion for Summary Judgment for Failing to Disclose the Best Mode, filed November 13, 2007;
- Declaration of Matthew A. Newboles in Support of Defendants' and Counterclaimants' Motion for Summary Judgment for Failing to Disclose the Best Mode, filed November 13, 2007;
- Memorandum of Points and Authorities in Support of Defendants' and Counterclaimants' Motion for Summary Judgment of Patent Invalidity for Violation of On Sale Bar and for Obviousness over the Prior Art, filed November 13, 2007;
- Declaration of Matthew A. Newboles in Support of Defendants' and Counterclaimants' Motion for Summary Judgment of Patent Invalidity for Violation of On Sale Bar and for Obviousness over the Prior Art, filed November 13, 2007;
- Memorandum of Points and Authorities in Support of Defendants' and Counterclaimants' Motion for Summary Judgment of Patent Invalidity for Lack of Enablement, filed November 13, 2007;
- Declaration of Matthew A. Newboles in Support of Defendants' and Counterclaimants' Motion for Summary Judgment of Patent Invalidity for Lack of Enablement, filed November 13, 2007;

- Memorandum of Points and Authorities in Support of Defendants' and Counterclaimants' Motion for Summary Judgment of Non-Infringement of the '566 Patent, filed November 13, 2007; and
- Declaration of Jeffrey Lavigne in Support of Defendants' and Counterclaimants' Motion for Summary Judgment Based on Non-Infringement of the '566 Patent, filed November 13, 2007.

With respect to the "Best Mode" issue, Immutopics alleged that the inventors of the '566 patent used a PTH (1-9) peptide to affinity purify an anti-PTH antibody before the Application No. 09/231,422, which issued as the '566 patent, was filed and the '566 patent fails to disclose the use of a PTH (1-9) peptide to affinity purify an anti-PTH antibody.

In the present application, the applicants submitted, on March 6, 2006, as part of a Response to a Non-Final Office Action, a replacement Figure 5, in which the portion of the title referring to Antibody As Tracer is amended to "with PTH 1-[[8]]₂ Antibody as Tracer." A Declaration of Thomas L. Cantor pursuant to 37 C.F.R § 1.132 (Cantor Decl.), explaining the reason for amending Figure 5, was also submitted with the March 6, 2006 Response.

In the reexamination of the '566 patent (Serial No. 90/007,685 and 90/007,732), the patent owner also submitted a replacement Figure 5 as part of a Response to the Non-Final Office Action on July 24, 2006. The Examiner in the reexamination of the '566 patent objected to the amendment of Figure 5 in the September 21, 2006 Final Office Action as adding new matter. (*See* the September 21, 2006 Final Office Action at pages 6-9.) The patent owner withdrew the amendment of Figure 5 as part of the November 10, 2006 Response to the Final Office Action in the reexamination of the '566 patent. (*See* the November 10, 2006 Response to the Final Office Action at page 13.) Patent owner's July 24, 2006 Response to the Non-Final Office Action was submitted as document number 25 in the Supplemental Information Disclosure Statement on September 8, 2006. The Examiner considered this document in the Office Action dated October 23, 2006. The September 21, 2006 Final Office Action was submitted as document number 24 in the Supplemental Information Disclosure Statement on November 2, 2006. The Examiner considered this document

in the Notice of Allowance dated January 4, 2007. Patent owner's November 10, 2006 Response to the Final Office Action in the reexamination of the '566 patent is submitted herewith as document number 12.

In a Supplemental Information Disclosure Statement submitted on May 10, 2005, applicants submitted Document numbers 204-223 from a pending civil action for patent infringement: *Scantibodies Laboratory, Inc. v. Immutopics, Inc.*, in the United States District Court for the Central District of California, Case No. CV04-8871 GPS (MANx) in connection with the present application. Applicants pointed out to the Examiner in the May 10, 2005 Supplemental Information Disclosure Statement:

- Document numbers 204 to 223 are from a pending civil action for patent infringement based on the '566 patent: *Scantibodies v. Immutopics*. Applicant wishes to bring the Examiner's attention to the following papers from this proceeding:
 - Defendants' Answer to Plaintiff's Complaint and Counterclaims, filed December 3, 2004 (Document No. 208 in the present Form PTO/SB/08a/b), in which unenforceability of the '566 patent is alleged;
 - Defendants' First Amended Answer to Plaintiff's Complaint and Counterclaims, filed December 21, 2004 (Document No. 210 in the present Form PTO/SB/08a/b), in which unenforceability of the '566 patent is alleged;
 - Defendants' Second Amended Answer to Plaintiff's Complaint and Counterclaims, filed December 31, 2004 (Document No. 211 in the present Form PTO/SB/08a/b), in which unenforceability of the '566 patent is alleged; and

- Plaintiff's Reply to Defendants' Counterclaims, filed January 27, 2005 (Document No. 212 in the present Form PTO/SB/08a/b), in which the alleged unenforceability of the '566 patent is denied.

The Examiner considered Document numbers 204 to 223 submitted with the May 10, 2005 Supplemental Information Disclosure Statement in the Office Action dated December 5, 2005.

U.S. Patent Application Serial No. 10/641,780 (the '780 application), filed August 15, 2003, is a continuation of U.S. Patent Application Serial No. 09/344,639 (the '639 application), filed June 26, 1999, now U.S. Patent No. 6,743,590, which is a continuation-in-part of U.S. Patent Application Serial No. 09/231,422 (the '422 application), filed January 14, 1999, now U.S. Patent No. 6,689,566. The '780 application is currently involved in an interference, Patent Interference No. 105,575 (MPT), with Immutopics' U.S. Patent No. 6,838,264 B2 ('264 patent).

Immutopics submitted Zahradnik List of Motions on October 11, 2007, in which Zahradnik alleges that the allowed claims of application number 10/641,780 are invalid and unenforceable. Applicants submitted Zahradnik List of Motions (as Document No. 6) in Supplemental Information Disclosure Statement on October 15, 2007. Immutopics also submitted the following motions in the interference on December 14, 2007:

- Zahradnik Substantive Motion 1 (Motion for Judgment Under 35 U.S. C. § 135(b)), filed December 14, 2007
- Zahradnik Substantive Motion 2 (Judgment for No Interference in Fact), filed December 14, 2007
- Zahradnik Substantive Motion 3 (Judgment for Lack of Written Description), filed December 14, 2007
- Zahradnik Substantive Motion 4 (Judgment for Lack of Enablement), filed December 14, 2007

Applicants submitted the four Zahradnik substantive motions listed above in a Supplemental Information Disclosure Statement on December 19, 2007.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 532212000623.

Dated: February 28, 2008

Respectfully submitted,

By 

Peng Chen

Registration No.: 43,543

MORRISON & FOERSTER LLP
12531 High Bluff Drive, Suite 100
San Diego, California 92130-2040
(858) 720-5117